Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRAMP: Golimumab and Apalutamide in CRPC
NCT05960578Phase 2Terminated
- Sponsor
- University of Washington
- Start
- May 2024
- Primary completion
- Jul 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of golimumab in castration-resistant prostate cancer (CRPC), sponsored by University of Washington. Started May 2024; status: terminated.
02
Drugs
golimumab
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT05960578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05960578.